Radioimmunotherapy with radioactive nanoparticles: Biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area
- 29 March 2010
- journal article
- radiation measurement-physics
- Published by Wiley in Medical Physics
- Vol. 37 (4) , 1826-1839
Abstract
Purpose: Radioactive atoms attached to monoclonal antibodies are used in radioimmunotherapy to treat cancer while limiting radiation to healthy tissues. One limitation of this method is that only one radioactive atom is linked to each antibody and the deposited dose is often insufficient to eradicate solid and radioresistant tumors. In a previous study, simulations with the Monte Carlo N‐Particle eXtended code showed that physical doses up to 50 Gy can be delivered inside tumors by replacing the single radionuclide by a radioactive nanoparticle of 5 nm diameter containing hundreds of radioactive atoms. However, tumoral and normal tissues are not equally sensitive to radiation, and previous works did not take account the biological effects such as cellular repair processes or the presence of less radiosensitive cells such as hypoxic cells. Methods: The idea is to adapt the linear‐quadratic expression to the tumor model and to determine biological effective doses (BEDs) delivered through and around a tumor. This BED is then incorporated into a Poisson formula to determine the shell control probability (SCP) which predicts the cell cluster‐killing efficiency at different distances “” from the center of the tumor. BED and SCP models are used to analyze the advantages of injecting radioactive nanoparticles instead of a single radionuclide per vector in radioimmunotherapy. Results: Calculations of BED and SCP for different distances from the center of a solid tumor, using the non‐small‐cell lung cancer as an example, were investigated for nanoparticles. With a total activity of about 3.5 and 20 MBq for tumor radii of 0.5 and 1.0 cm, respectively, results show that a very high BED is deposited in the well oxygenated part of the spherical carcinoma. Conclusions: For either small or large solid tumors, BED and SCP calculations highlight the important benefit in replacing the single ‐emitter attached to each antibody by a nanoparticle.Keywords
Funding Information
- Walloon Region
This publication has 56 references indexed in Scilit:
- Use of antibodies and immunoconjugates for the therapy of more accessible cancersAdvanced Drug Delivery Reviews, 2008
- Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”European Journal of Nuclear Medicine and Molecular Imaging, 2007
- Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapyPhysics in Medicine & Biology, 2006
- Hybrid gold nanoparticles in molecular imaging and radiotherapyCzechoslovak Journal of Physics, 2006
- The Radiobiology of Conventional Radiotherapy and Its Application to Radionuclide TherapyCancer Biotherapy and Radiopharmaceuticals, 2005
- A TCP‐NTCP estimation module using DVHs and known radiobiological models and parameter setsJournal of Applied Clinical Medical Physics, 2004
- Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapyRadiotherapy and Oncology, 2004
- Parameter dependence of the MCNP electron transport in determining dose distributionsMedical Physics, 2002
- Dose-rate effects in targeted radiotherapyPhysics in Medicine & Biology, 1996
- The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapyBritish Journal of Radiology, 1985